RETRACTED: Open Innovation in R&amp;D

Maamari, Bassem E.; Osta, Alfred

doi:10.4018/ijkm.296261

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Academic and clinical evidence remain to be solved, and studies on open innovation and other related topic are addressing specific scientific and economic impacts of open innovation [56]. Within open innovation, co-patenting is a possible solution that accelerates successful transformation of the new digital value chain in the biopharmaceutical industry [57]. The general mechanism is that open innovation allows more dynamic invite for and convergence with external intelligence as well as resources in each innovation process [53].…”

Section: Discussion: New Pharmaceutical Value Chain Model With Digita...mentioning

confidence: 99%

A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

Kim

Atukeren²,

Lee³

2022

Journal of Open Innovation: Technology, Market, and Complexity

View full text Add to dashboard Cite

The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate with the product-life-cycle perspective to better explain the drug development process changes and how the digital transformation could be implemented at each stage of the drug development process. We suggest a new framework to capture digital value creation in the biopharmaceutical industry by focusing on the specific processes in new drug development and integrating the product life cycle management and value chain model. The new framework has operational implications for the biopharmaceutical industry, where digital transformation can simplify and increase the efficiency in each phase, from drug discovery, clinical trials, regulatory, manufacturing, commercialization, to monitoring processes.

show abstract

Section: Discussion: New Pharmaceutical Value Chain Model With Digita...mentioning

confidence: 99%

A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

Kim

Atukeren²,

Lee³

2022

Journal of Open Innovation: Technology, Market, and Complexity

View full text Add to dashboard Cite

show abstract

Interdependencies between international innovation partnerships: the case of Central and Eastern Europe

Bašić,

Vlajčić,

Grgić

2023

View full text Add to dashboard Cite

Purpose Competitively multipolar international system demands bilateral and multilateral partnerships. Joint innovation signals close partnerships. Regional proximity of Central and Eastern Europe (CEE) to the European Union (EU) defines its research and development objectives. These objectives are additionally subjected to the USA’s geopolitical strategy in this geographical area. Hence, CEE’s limited resources require limited resources make international innovation cooperation. This paper aims to analyse whether and how CEE countries make international innovation cooperation decisions. Design/methodology/approach This paper used Organisation for Economic Co-operation and Development (OECD) database of total patent applications filed to the patent cooperation treaty (PCT) with co-applicants from abroad, where co-patents with at least one foreign inventor present a measure of international innovation partnership. A vector autoregression analysis and impulse response function were used to analyse international innovation partnership choices of eight CEE OECD countries for the period 1990–2018. Findings Innovation with the EU is of collaborative nature, commonly displaying complementary properties with the rest of the examined innovation partners, while co-patenting with the Russia and China act as substitutes or complements. Co-patenting with Russia is the most versatile, displaying both properties of collaboration and competition. Some countries exhibit complementarity in co-patenting activities with multiple partners. The significance levels of these relationships vary, indicating varying degrees of impact. Overall, these findings highlight the complex dynamics of co-patenting activities and the influence of different partners on countries’ collaborative innovation strategies. Research limitations/implications In addition to significant relationships, insignificant relationships as well as those that could bring about greater synergy are flagged in the paper. Those relationships portray possible direction into which national funds could be channelled to incite cooperation between different sectors and countries, especially as innovation partnerships are not always successful and require a long time period to materialise. Originality/value By examining bilateral innovation partnerships, this study provides an insight into the strategic political and economic spheres of influence in the CEE region.

show abstract

Divide and conquer: Relating patent quality and value in a conceptual framework based on a systematic review

Ananthraman,

Cambré,

Kittler

et al. 2023

Int J Management Reviews

View full text Add to dashboard Cite

Patents as intangible assets are subjects of burgeoning empirical research. However, there is limited knowledge of how patent quality and patent value can be conceptualized, distinguished, and related. Distinguishing these concepts and relating them in a theoretical framework would enable the assessment and improvement of patent quality, which has implications for all the stakeholders in patents. We ground this study in the emergent ex‐ante theory of patent value and conduct a systematic review of 340 papers that investigate patent quality or value. Based on a comparative analysis of the patentability standards adopted by the patent offices in the United States, Europe, and Japan, we delineate four dimensions of patent quality—subject matter, utility, non‐obviousness or inventive step, and sufficiency of disclosure. Our study contributes to theory by providing an elaborated conceptual model that relates the different dimensions of patent quality and patent value and mapping the different types of indicators of patent quality and value onto the corresponding patent quality or value dimensions. Our study suggests that patent policymakers can incentivize innovators to file patent applications of high quality, which would reduce the incidence of poor‐quality patents in the system and improve the efficiency and reputation of the patent office.

show abstract

RETRACTED: Open Innovation in R&D

Cited by 4 publications

References 53 publications

A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

Interdependencies between international innovation partnerships: the case of Central and Eastern Europe

Divide and conquer: Relating patent quality and value in a conceptual framework based on a systematic review

Contact Info

Product

Resources

About